MenSC Labs offers two main products as part of our end-to-end solution. First, our proprietary collection and preservation system enables women to safely collect and transfer menstrual blood from home while ensuring that the mesenchymal stem cells remain viable. Second, our AI/ML model analyzes patient data and mesenchymal stem cell surface markers to assess the viability of menstrual blood for therapeutic applications. Our initial focus is on dermatological applications, leveraging the accessibility of this market, but we aim to expand into conditions like endometriosis and Asherman’s syndrome, supported by promising research.  Unlike any other company, MenSC Labs provides a process that unlocks the therapeutic potential of menstrual blood. Thus, our primary competitor is other sources of stem cells, particularly bone marrow stem cells (BMSCs), which are considered the gold standard. However, MenSCs offer distinct advantages: they require no invasive procedures to obtain, are abundantly available, and have superior properties, including higher CFUs, greater angiogenic effects, enhanced migration ability, and a better paracrine response.